Search | Page 17 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. More is better: Combination therapies for myelodysplastic syndromes

    ... FDA-approved medications for MDS: lenalidomide , azacitidine , and decitabine .  Although these agents can be ... therapy is using an epigenetic approach, where one combines azacitidine or decitabine (the class of drugs known as hypomethylating agents) ...

    Research Review last updated 05/02/2016 - 9:14am.

  2. Recent developments in myelodysplastic syndromes

    ... were approved for MDS between the years 2004 – 2006 ( azacitidine , decitabine , and lenalidomide ), none of these ... or molecular markers have consistently predicted response to azacitidine or decitabine.  -There are several novel agents and combinations ...

    Research Review last updated 05/02/2016 - 9:16am.

  3. Pathogenesis of MDS: An overview of molecular and non-molecular aspects of the disease

    ... FDA-approved medications for MDS: lenalidomide , azacitidine , and decitabine .  Although these agents can be ... to have better responses to hypomethylating agents, such as azacitidine and decitabine. Splicing factor genes are mutated in about 50% ...

    Research Review last updated 05/02/2016 - 9:14am.

  4. A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

    ... to an Erythropoiesis Stimulating Agent (ESA) and/or Azacitidine (AZA) followed by a dose expansion part with an additional 30 ...

    Clinical Trial last updated 04/28/2016 - 4:14pm.

  5. Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

    ... agent (such as decitabine [Vidaza] and azacitidine [AZA]). Status:  ...

    Clinical Trial last updated 04/28/2016 - 12:21pm.

  6. Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

    ... failure of treatment with a hypomethylating agent (HMA), azacitidine (AZA) or decitabine (DEC). ...

    Clinical Trial last updated 04/27/2016 - 12:49pm.

  7. Sexuality and Intimacy

    ... and joint pain. Hypomethlyating agents like azacitidine (Vidaza®) can cause nausea/vomiting, diarrhea, fatigue ...

    Page last updated 05/02/2016 - 10:09am.

  8. Sapacitibine shows promise for high-risk MDS patients

    ... drugs approved by the Food and Drug Administration are azacitidine (5-AZA, Vidaza®) and decitabine (Dacogen®). Both of ...

    Research Review last updated 05/02/2016 - 9:30am.

  9. Selinexor (KPT-330) in Older Patients With Relapsed/Refractory AML (SOPRA)

    ... Associated Drug(s):  Azacitidine Decitabine Selinexor (KPT-330) ...

    Clinical Trial last updated 08/26/2016 - 9:21am.

  10. Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation

    ... of 200 patients who were treated with Vidaza® ( azacitidine ), Dacogen® ( decitabine ), or both azacitidine and decitabine. The 76 patients in Cohort 2 underwent a stem ...

    Research Review last updated 05/02/2016 - 9:26am.